Condition: Multiple Myeloma · Sponsor: AbbVie
Multiple myeloma (MM) is a plasma cell disease characterized by the growth of clonal plasma cells in the bone marrow. The purpose of this study is to assess the safety and change in disease activity of surzetoclax in adult participants with relapsed/refractory (R/R) MM. Adverse events and change in disease activity will be assessed. Surzetoclax is an investigational drug being developed for the treatment of R/R MM. In Substudy 1 there will be a dose escalation phase where participants will receive various doses of surzetoclax in combination with daratumumab + dexamethasone, to determine the best dose of surzetoclax. This will be followed by a dose expansion and selection phase where participants will receive 1 of 2 doses of surzetoclax in combination with daratumumab + dexamethasone, or daratumumab + dexamethasone + pomalidomide (only during the expansion phase). In Substudy 2, there will be a dose escalation phase where participants will receive various doses of surzetoclax alone. Approximately 130 adult participants with R/R MM will be enrolled in the study in approximately 40 sites worldwide. In Substudy 1 escalation phase, participants will receive oral surzetoclax tablets in combination with subcutaneous (SC) daratumumab injections + oral dexamethasone tablets and in the expansion phase, will receive oral surzetoclax tablets in combination with SC daratumumab injections + oral dexamethasone tablets or daratumumab injections + oral pomalidomide + oral dexamethasone tabl…
This description comes directly from the study's public registry record.
ABBVIE CALL CENTER · 844-663-3742 · abbvieclinicaltrials@abbvie.com
Always discuss trial participation with your own doctor first.
| University of Southern California /ID# 272414 | Los Angeles, California, United States | Recruiting |
| Yale University School of Medicine /ID# 272447 | New Haven, Connecticut, United States | Recruiting |
| Dana-Farber Cancer Institute /ID# 271846 | Boston, Massachusetts, United States | Recruiting |
| University of Michigan Health System - Ann Arbor /ID# 271536 | Ann Arbor, Michigan, United States | Recruiting |
| Memorial Sloan Kettering Cancer Center - New York - York Avenue /ID# 271214 | New York, New York, United States | Recruiting |
| University of North Carolina at Chapel Hill /ID# 272454 | Chapel Hill, North Carolina, United States | Recruiting |
| Atrium Health Levine Cancer Institute /ID# 271510 | Charlotte, North Carolina, United States | Recruiting |
| Wake Forest Baptist Health /ID# 271294 | Winston-Salem, North Carolina, United States | Recruiting |
| Oregon Health and Science University /ID# 272282 | Portland, Oregon, United States | Recruiting |
| University of Texas - Southwestern Medical Center /ID# 271914 | Dallas, Texas, United States | Recruiting |
| Northwest Medical Specialties Tacoma /ID# 272506 | Tacoma, Washington, United States | Recruiting |
| Liverpool Hospital /ID# 272002 | Liverpool, New South Wales, Australia | Recruiting |
+ 36 more locations — full list on the registry record.
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT06953960